Travere Therapeutics Inc (TVTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Travere Therapeutics Inc (Travere Therapeutics), formerly Retrophin Inc, is a biopharmaceutical company that discovers, develops, and commercializes drugs for the treatment of rare diseases. The company’s products include thiola, chenodal, and cholbam. It develops drugs for therapies for people living with liver, rare kidney and metabolic diseases. Travere Therapeutics' marketed product Filspari (sparsentan), is developed to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Its pipeline products include sparsentan which is being developed for the treatment of focal segmental glomerulosclerosis and Pegtibatinase (TVT-058) being developed for the treatment of classical homocystinuria (HCU). The company markets its products through its distribution partners. It works in partnership with academia and independent researchers to support the development of novel solutions. Travere Therapeutics is headquartered in San Diego, California, the US.Travere Therapeutics Inc Key Recent Developments
- May 06, 2024: Travere Therapeutics Reports First Quarter 2024 Financial Results
- Mar 14, 2024: IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
- Feb 15, 2024: Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
- Nov 07, 2023: Travere Therapeutics Reports Third Quarter 2023 Financial Results
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company Financial Ratios
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Section 5 - Company’s Recent Developments
Section 6 - Appendix
List of Tables
List of Figures
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pharmesis International Ltd
- Eledon Pharmaceuticals Inc
- Alpine Immune Sciences Inc
- Acelyrin Inc
- Stada Arzneimittel AG
- SciClone Pharmaceuticals Holdings Ltd
- Omeros Corp
- MorphoSys AG
- Ginkgo Bioworks Holdings Inc
- DiaMedica Therapeutics Inc
- Voyager Therapeutics Inc
- Takeda Pharmaceuticals USA Inc
- Novartis AG
- Leadiant Biosciences Inc
- BioCryst Pharmaceuticals Inc
- AstraZeneca Plc
- Calliditas Therapeutics US Inc
- Viatris Pharmaceuticals Japan Inc
- Teva Pharmaceuticals USA Inc
- Par Pharmaceutical Inc
- AbbVie Inc
- Vera Therapeutics Inc
- Torrent Pharmaceuticals Ltd
- Everest Medicines US Ltd
- Arrowhead Pharmaceuticals Inc
- Synlogic Inc
- Roche Holding AG
- Otsuka Corp
- Jiangsu Hengrui Medicine Co Ltd
- Ionis Pharmaceuticals Inc
- CoA Therapeutics Inc
- Intercept Pharmaceuticals Inc
- Human Immunology Biosciences Inc
- Falk Pharma Gmbh
- Boehringer Ingelheim International GmbH
- Advicenne SA